Thiazolyl peptide antibiotics, nocathiacin I, II and III, were identified in a culture of Nocardia sp. WW-12651 (ATCC 202099). They exhibit potent in vitro activity (ng/ml) against a wide spectrum of Gram-positive bacteria, including multiple-drug resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistant Enterococcus faecium (MREF) and fully penicillin-resistant Streptococcus pneumoniae (PRSP), and demonstrate excellent in vivo efficacy in a systemic Staphylococcus aureus infection mice model.
Multidrug-resistant strains of many clinically important pathogenic bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, Mycobacterium tuberculosis, and Enterococcus strains are becoming a worldwide health problem1,2). There is an urgent need to discover new agents to treat patients infected with multidrug-resistant bacteria3-5). A new group of thiazolyl peptide antibiotics (designated herein as nocathiacins) was discovered in the course of screening for novel antibiotics in a multi-drug resistant Enterococcus faecium (MREF) assay. The nocathiacins I-III ( Fig. 1) were isolated from culture broth of Nocardia sp. WW-12651 (ATCC-202099) and share structural similarities to the glycothiohexides6-8), thiostrepton9), nosiheptide10), micrococcins11), GE2270 A12), cyclothiazomycin13) and berninamycin14). MJ347-81F4-A15), produced by Amycolatopsis sp., was reported to have the same general structure as that of nocathiacin I, but its spectral data and absolute configuration were not reported. This paper deals with the taxonomy of the producing strain, fermentation, and biological activities of nocathiacins I-III. The isolation and structural elucidation of these compounds will be reported elsewhere16,17). 
Discussion
Drug-resistant pathogens are a growing concern, with some strains being resistant to multiple antibiotic agents.
antibiotics, macrolides, quinolones, and vancomycin is becoming a major worldwide health problem. A significant problem in clinical practice is the increase in incidence of MRSA strains. MRSA infections have traditionally been treated with vancomycin. However, there are recent reports of emerging vancomycin resistance in some MRSA isolates. MREF continues to be problematic therapeutically due to intrinsic resistance to antimicrobial agents. Of particular concern is the emerging resistance worldwide of the important community acquired pathogen Streptococcus pneumoniae to penicillin and other antibacterials. Therefore there is an urgent need to discover new agents to treat Like nosiheptide23), the aglycone portion of nocathiacins appear to be derived from amino acids. We speculated that the attachment of the amino sugar in nocathiacin I was at the late stage of biosynthesis. Nocathiacin III (aglycone) was not observed under the initial fermentation conditions, which we reasoned was due to high glycosidation rate at (250rpm) conditions. Indeed, nocathiacin III was detected at lower fermentation temperatures and lower agitation rates, and was consumed with prolonged incubation with concomitant increase in the titer of nocathiacin I, suggesting that nocathiacin III was a close precursor of nocathiacin I. Further biosynthetic studies are necessary to address the questions.
